FoRx Therapeutics raises USD 50 M

FoRx Therapeutics develops FORX-428, an oral PARG enzyme inhibitor for advanced solid tumours, now in Phase 1 trials. The USD 50 million Series A, including the first close from June 2024, will fund the trial through to first results.

Announced on
Round
Series A
Amount
USD 50 M
Location
Basel, canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic